Opportunity Information: Apply for PA 09 004
Apply for PA 09 004
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery(R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399 Cancer Control.
- This funding opportunity was created on Oct 6, 2008 and posted on Oct 6, 2008.
- Applicants must submit their applications by Jan 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments State governments Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Private institutions of higher education For profit organizations other than small businesses Special district governments.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Non domestic (non U.S.) Entities (Foreign Organizations) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This National Cancer Institute (NCI) Funding Opportunity Announcement (FOA) supports health services research focused on how emerging cellular, molecular, and genetic/genomic (CMG) technologies are actually being used in real-world cancer care and what that use means for patients, providers, health systems, and outcomes. The core idea is not to develop new laboratory methods, but to study the downstream effects of CMG tools once they enter clinical workflows, including technologies that are already commercially available and being used today, as well as later-stage tools that are close to broader adoption (for example, in advanced development or moving through regulatory review). The FOA also pushes applicants to bridge disciplines, encouraging collaborations between health services researchers and clinical and/or translational scientists so that studies stay grounded in both implementation realities and the science behind these tools.
The research scope is broad but very clearly organized around practical questions that matter to cancer care delivery. Projects are expected to evaluate CMG technologies in relation to quality of care, meaning how these tools affect whether patients receive appropriate, timely, evidence-based services and whether care processes improve or become more complicated. A major emphasis is understanding organizational barriers and change factors, such as what helps or prevents hospitals, clinics, and provider groups from adopting CMG technologies appropriately, how staffing and training issues affect use, and how workflow, incentives, leadership, information systems, and local culture shape implementation. Applicants are also encouraged to tackle cost and cost-effectiveness, including how CMG tools influence spending for patients and payers, whether they reduce unnecessary procedures or lead to additional testing, and under what conditions the health benefits justify added costs.
A central priority is identifying and explaining disparities in access and efficacy. That includes studying whether certain populations (by race/ethnicity, income, geography, insurance status, rural versus urban location, or other factors) are less likely to receive CMG-based testing or treatments, as well as whether the clinical benefits are the same across groups once the technology is used. The FOA also highlights the importance of monitoring cross-sectional patterns of care and time trends, which points to studies that track uptake across different settings and how adoption changes over time, potentially capturing diffusion, overuse, underuse, or shifting practice norms. Another key theme is how CMG technologies affect existing standards of care, including whether they change diagnostic pathways, alter treatment selection, replace older approaches, or create new decision points that clinicians and patients must navigate.
Importantly, this FOA is oriented toward outcomes that matter at both the patient and population levels. Applicants are invited to examine how CMG technologies influence cancer outcomes such as incidence, progression, mortality, survival, and quality of life. That framing allows for studies that look at short-term clinical and service outcomes (like treatment choice, adherence, complications, or time to therapy) as well as longer-term endpoints. In practice, competitive projects would typically connect technology use to measurable impacts on care delivery and patient health, while also addressing context such as setting, population, and organizational capacity.
Funding is provided through the NIH Research Project Grant (R01) mechanism, which is designed for more mature, fully developed research projects rather than small pilot efforts. This FOA runs in parallel with a separate announcement of the same scientific scope that uses the R21 mechanism (exploratory/developmental), which signals that NCI is supporting both early idea-generation work (R21) and larger, more definitive studies (R01). Awards depend on the availability of funds and on the submission of a sufficient number of scientifically strong, competitive applications; in other words, there is no guaranteed number of awards listed here, and funding is contingent on merit and budget conditions.
Eligibility is broad and includes many types of organizations that might conduct health services and cancer care delivery research. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including but not limited to those with 501(c)(3) status), for-profit organizations (including small businesses and other for-profits), and government entities at the state, county, city/township, and special district levels. The eligibility language also includes independent school districts and other categories clarified in the full FOA text, along with additional eligible applicants such as certain federal agencies, faith-based or community-based organizations, Hispanic-serving institutions, U.S. territories or possessions, and non-U.S. entities (foreign organizations). There is no cost-sharing or matching requirement stated for this opportunity.
Administrative details in the source listing show the FOA number as PA-09-004, categorized as a discretionary grant in the health/education area under CFDA 93.399 (Cancer Control). The opportunity was posted on October 6, 2008, with an original and current closing date of January 7, 2012, and an archive date of February 7, 2012, indicating that it is no longer an active open solicitation as of that archive date. The full announcement was hosted through the NIH grants guide, and contact support is routed through the NIH Office of Extramural Research (OER) webmaster for technical access issues.
Frequently Asked Questions (FAQ)
1) What is the main purpose of this NCI funding opportunity?
This National Cancer Institute (NCI) Funding Opportunity Announcement (FOA) supports health services research that examines how emerging cellular, molecular, and genetic/genomic (CMG) technologies are used in real-world cancer care and what that real-world use means for patients, providers, health systems, and outcomes.
2) Is this FOA meant to fund development of new laboratory tests or methods?
No. The core idea is not to develop new laboratory methods. The focus is on studying downstream effects after CMG tools enter clinical workflows, including their implementation, impact on care delivery, and outcomes.
3) What types of CMG technologies are in scope?
The FOA includes CMG technologies that are already commercially available and currently used in clinical care, as well as later-stage tools that are close to broader adoption (for example, in advanced development or moving through regulatory review).
4) What kinds of research questions does the FOA encourage?
Projects are expected to evaluate CMG technologies in practical, care-delivery-focused ways, including impacts on quality of care, organizational adoption and implementation factors, costs and cost-effectiveness, disparities, patterns and trends in uptake, and how CMG tools change standards of care and clinical decision-making.
5) What does "quality of care" mean in the context of this FOA?
Quality of care is framed around how CMG tools affect whether patients receive appropriate, timely, evidence-based services and whether care processes improve or become more complicated once these technologies are used in routine practice.
6) Does the FOA emphasize implementation and organizational factors?
Yes. A major emphasis is understanding organizational barriers and change factors that affect adoption and appropriate use. Examples include staffing and training, workflow integration, incentives, leadership, information systems, and local culture within hospitals, clinics, and provider groups.
7) Are studies on costs and cost-effectiveness allowed or encouraged?
Yes. Applicants are encouraged to study cost and cost-effectiveness, such as how CMG tools influence spending for patients and payers, whether they reduce unnecessary procedures or lead to additional testing, and under what conditions health benefits justify added costs.
8) Does this FOA prioritize research on disparities?
Yes. A central priority is identifying and explaining disparities in access and efficacy, including whether certain populations are less likely to receive CMG-based testing or treatments and whether benefits differ across groups once the technology is used.
9) What kinds of populations or disparity dimensions are mentioned?
The FOA highlights disparities by factors such as race/ethnicity, income, geography, insurance status, and rural versus urban location, as well as other factors that may shape access and outcomes.
10) Does the FOA support studies of uptake patterns and trends over time?
Yes. The FOA highlights monitoring cross-sectional patterns of care and time trends, including tracking uptake across settings and how adoption changes over time, potentially capturing diffusion, overuse, underuse, or shifting practice norms.
11) Can projects examine how CMG technologies change standards of care?
Yes. A key theme is how CMG technologies affect existing standards of care, including whether they change diagnostic pathways, alter treatment selection, replace older approaches, or create new decision points for clinicians and patients.
12) What outcomes are considered relevant for this FOA?
The FOA is oriented toward outcomes at both patient and population levels. Examples include cancer incidence, progression, mortality, survival, and quality of life, as well as shorter-term clinical and service outcomes like treatment choice, adherence, complications, or time to therapy.
13) Does the FOA require collaboration across disciplines?
It encourages bridging disciplines, specifically collaborations between health services researchers and clinical and/or translational scientists, to keep studies grounded in both implementation realities and the underlying science of CMG tools.
14) What grant mechanism is used for this opportunity?
Funding is provided through the NIH Research Project Grant (R01) mechanism, which is intended for more mature, fully developed research projects rather than small pilot efforts.
15) Is there a related opportunity for exploratory or developmental work?
Yes. This FOA runs in parallel with a separate announcement of the same scientific scope that uses the R21 mechanism (exploratory/developmental), indicating support for both early-stage idea generation (R21) and larger definitive studies (R01).
16) Is the number of awards guaranteed?
No. Awards depend on the availability of funds and on receiving a sufficient number of scientifically strong, competitive applications. No guaranteed number of awards is stated in the information provided.
17) Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofit organizations (including those with 501(c)(3) status), for-profit organizations (including small businesses), and government entities at state, county, city/township, and special district levels. The eligibility language also includes independent school districts and additional eligible applicants such as certain federal agencies, faith-based or community-based organizations, Hispanic-serving institutions, U.S. territories or possessions, and foreign (non-U.S.) organizations.
18) Are foreign (non-U.S.) organizations eligible?
Yes. The eligibility listing explicitly includes non-U.S. entities (foreign organizations).
19) Is cost-sharing or matching required?
No cost-sharing or matching requirement is stated for this opportunity.
20) What is the FOA number and program classification information?
The FOA number is PA-09-004. It is categorized as a discretionary grant in the health/education area under CFDA 93.399 (Cancer Control).
21) Is this FOA currently open?
No. The opportunity was posted on October 6, 2008, with an original and current closing date of January 7, 2012, and an archive date of February 7, 2012. Based on those dates, it is no longer an active open solicitation.
22) Where was the full announcement hosted, and who handles technical access issues?
The full announcement was hosted through the NIH grants guide. For technical access issues, support is routed through the NIH Office of Extramural Research (OER) webmaster.
Browse more opportunities from the same category: Education Health
Next opportunity: Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery (R21)
Previous opportunity: Short Courses on Mathematical, Statistical, and Computational Tools for Studying Biological Systems (R25)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 004
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 004) also looked into and applied for these:
| Funding Opportunity |
|---|
| Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery (R21) Apply for PA 09 005 Funding Number: PA 09 005 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R21) Apply for PA 08 264 Funding Number: PA 08 264 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R03) Apply for PA 08 265 Funding Number: PA 08 265 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21) Apply for PA 08 267 Funding Number: PA 08 267 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Interactions between Physical Activity and Drug Abuse (R01) Apply for RFA DA 09 013 Funding Number: RFA DA 09 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interactions between Physical Activity and Drug Abuse (R03) Apply for RFA DA 09 014 Funding Number: RFA DA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic and Preclinical Research on Complementary and Alternative Medicine (CAM) (R01) Apply for PA 09 010 Funding Number: PA 09 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Mouse Gene Development Initiative (R01) Apply for RFA DA 09 015 Funding Number: RFA DA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medical Management of Older Patients with HIV/AIDS (R01) Apply for PA 09 017 Funding Number: PA 09 017 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R01) Apply for PA 09 020 Funding Number: PA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| International Research Collaboration on Drug Abuse and Addiction Research (R21) Apply for PA 09 021 Funding Number: PA 09 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R03) Apply for PA 09 022 Funding Number: PA 09 022 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R21) Apply for RFA DA 09 018 Funding Number: RFA DA 09 018 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Secondary Data Analyses for Substance Abuse Research (R21/R33) Apply for RFA DA 09 020 Funding Number: RFA DA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Brain Imaging Studies of Negative Reinforcement in Humans (R01) Apply for RFA DA 09 008 Funding Number: RFA DA 09 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Brain Imaging Studies of Negative Reinforcement in Humans (R21) Apply for RFA DA 09 009 Funding Number: RFA DA 09 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Instrument Development for Biomedical Applications (R21) Apply for RFA RR 09 001 Funding Number: RFA RR 09 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Erythropoiesis Stimulating Agents and Tumor Progression (R01) Apply for PA 09 023 Funding Number: PA 09 023 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Erythropoiesis Stimulating Agents and Tumor Progression (R21) Apply for PA 09 024 Funding Number: PA 09 024 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cancer Institute Program Project (P01) Applications Apply for PAR 09 025 Funding Number: PAR 09 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.